30-Jun-2025 6:00 AM CST - Business Wire Novocure to Report Second Quarter 2025 Financial Results Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 24, to discuss the companys financial results for the three- and six-month periods that ended June 30, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided.
27-May-2025 6:00 AM CST - Business Wire Novocure Announces Upcoming Investor Events Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00 p.m. CT in Chicago to review data from the successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreatic cancer. Novocure leadership will be joined by Vincent Picozzi, MD, MMM, medical oncologist and investigator in the
24-Apr-2025 6:00 AM CST - Business Wire Novocure Reports First Quarter 2025 Financial Results Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). This is a period of meaningful momentum for Novocure, said Ashley Cordova, CEO Novocure. After years in a single commercial indication, our footprint is ex
1-Apr-2025 6:00 AM CST - Business Wire Novocure to Report First Quarter 2025 Financial Results Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 24, to discuss the companys financial results for the three-month quarter that ended March 31, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To acce
4-Mar-2025 6:00 AM CST - Business Wire Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 4:20 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be accessed from the Investor Relations page of Novocures website, www.novocure.com/investor-relations, a
31-Oct-2024 9:36 AM CST - Business Wire Novocure meldet Finanzergebnisse des dritten Quartals 2024 Novocure (NASDAQ: NVCR) hat heute seine Finanzergebnisse fr das am 30. September 2024 beendete dritte Quartal gemeldet. Novocure ist ein globales Onkologieunternehmen, das daran arbeitet, die berlebenszeit bei einigen der aggressivsten Krebsarten durch die Entwicklung und Vermarktung seiner innovativen Therapie, Tumor Treating Fields (TTFields), zu verlngern. Diese Periode war durch einen guten Geschftsverlauf und herausragende Leistungen bei Novocure gekenn
30-Jun-2025 6:00 AM CST - Business Wire Novocure to Report Second Quarter 2025 Financial Results Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 24, to discuss the companys financial results for the three- and six-month periods that ended June 30, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided.
27-May-2025 6:00 AM CST - Business Wire Novocure Announces Upcoming Investor Events Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00 p.m. CT in Chicago to review data from the successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreatic cancer. Novocure leadership will be joined by Vincent Picozzi, MD, MMM, medical oncologist and investigator in the
24-Apr-2025 6:00 AM CST - Business Wire Novocure Reports First Quarter 2025 Financial Results Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). This is a period of meaningful momentum for Novocure, said Ashley Cordova, CEO Novocure. After years in a single commercial indication, our footprint is ex
1-Apr-2025 6:00 AM CST - Business Wire Novocure to Report First Quarter 2025 Financial Results Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 24, to discuss the companys financial results for the three-month quarter that ended March 31, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To acce
4-Mar-2025 6:00 AM CST - Business Wire Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 4:20 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be accessed from the Investor Relations page of Novocures website, www.novocure.com/investor-relations, a
31-Oct-2024 9:36 AM CST - Business Wire Novocure meldet Finanzergebnisse des dritten Quartals 2024 Novocure (NASDAQ: NVCR) hat heute seine Finanzergebnisse fr das am 30. September 2024 beendete dritte Quartal gemeldet. Novocure ist ein globales Onkologieunternehmen, das daran arbeitet, die berlebenszeit bei einigen der aggressivsten Krebsarten durch die Entwicklung und Vermarktung seiner innovativen Therapie, Tumor Treating Fields (TTFields), zu verlngern. Diese Periode war durch einen guten Geschftsverlauf und herausragende Leistungen bei Novocure gekenn
